RFW
ORMP icon

Redwood Family Wealth’s Oramed Pharmaceuticals ORMP Stock Holding History

Redwood Family Wealth’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.8K Sell
20,745
-1,320
-6% -$5.25K 0.09% 105
2026
Q1 		$75K Sell
22,065
-935
-4% -$3.17K 0.07% 98
2025
Q4 		$65.5K Buy
+23,000
New +$59.3K 0.06% 104

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redwood Family Wealth's ORMP Position: Q2 2026 in Review

Redwood Family Wealth reduced its Oramed Pharmaceuticals (ORMP) stake by 6% in Q2 2026, selling an estimated $5.25K and leaving 20,745 shares worth $99.8K. The position accounts for 0.09% of the portfolio, ranked #105.

Redwood Family Wealth first reported a position in ORMP in Q4 2025 and has held it in 3 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Redwood Family Wealth held 20,745 shares of Oramed Pharmaceuticals worth $99.8K as of Q2 2026.
  • Redwood Family Wealth sold 1,320 Oramed Pharmaceuticals shares in Q2 2026, an estimated $5.25K.
  • Oramed Pharmaceuticals made up 0.09% of Redwood Family Wealth's portfolio in Q2 2026, its #105 holding.
  • Redwood Family Wealth first reported a position in Oramed Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Redwood Family Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.